We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Entasis Therapeutics Holdings Inc | NASDAQ:ETTX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.19 | 2.21 | 2.19 | 0 | 01:00:00 |
Event: BMO Capital Markets 2018 Prescriptions for Success Healthcare ConferenceDate: December 12, 2018 at 2:00 PM ETLocation: Mandarin Oriental Hotel, New York, NY
A live webcast of the presentation can be accessed under "Investors & Media" in the “News & Events” section of the Company's website at www.entasistx.com.
About EntasisEntasis Therapeutics is developing a portfolio of innovative product candidates to treat serious Gram-negative multi-drug resistant bacterial infections. Entasis’ anti-infective discovery platform has produced a pipeline of meaningfully differentiated programs which target serious bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae), ETX0282CPDP (targeting Enterobacteriaceae infections), and non-β-lactam PBP inhibitors or NBPs (targeting Gram-negative infections). www.entasistx.com
Company Contact Kyle Dow Entasis Therapeutics (781) 810-0114 kyle.dow@entasistx.com
Investor ContactChris BrinzeyWestwicke Partners(339) 970-2843Chris.brinzey@westwicke.com
Media ContactKari Watson or Stefanie TuckMacDougall Biomedical Communications(781) 235-3060kwatson@macbiocom.com or stuck@macbiocom.com
1 Year Entasis Therapeutics Chart |
1 Month Entasis Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions